HRT Financial’s Highland Transcend Partners I Corp. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 HTPA.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-33,315
Closed -$1K 3783
2022
Q3
$1K Hold
33,315
﹤0.01% 2693
2022
Q2
$4K Hold
33,315
﹤0.01% 2767
2022
Q1
$10K Buy
+33,315
New +$34.7K ﹤0.01% 2904

HRT Financial's HTPA.WS Position: Q4 2022 in Review

HRT Financial sold out of Highland Transcend Partners I Corp. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 (HTPA.WS) in Q4 2022, closing a stake of 33,315 shares — an estimated $1K sold.

HRT Financial first reported a position in HTPA.WS in Q1 2022 and held it in 3 quarters. The position peaked at $10K in Q1 2022. 0 funds tracked by Wall St. Rank hold HTPA.WS as of Q4 2022.

  • HRT Financial reported no remaining Highland Transcend Partners I Corp. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 position as of Q4 2022 after selling out during the quarter.
  • HRT Financial sold 33,315 Highland Transcend Partners I Corp. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 shares in Q4 2022, an estimated $1K.
  • HRT Financial first reported a position in Highland Transcend Partners I Corp. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 in Q1 2022 and held it in 3 quarters.
  • HRT Financial's Highland Transcend Partners I Corp. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 position peaked at $10K in Q1 2022.
  • 0 funds tracked by Wall St. Rank held Highland Transcend Partners I Corp. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 as of Q4 2022.

Based on HRT Financial's 13F filing for Q4 2022, filed 10 Feb 2023.